Pulmonary Arterial Hypertension
Pipeline by Development Stage
Drug Modality Breakdown
On Market (10)
Approved therapies currently available
Competitive Landscape
23 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 4,130 patients across 50 trials
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension
An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension
Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)
Treprostinil Combined With Tadalafil for Pulmonary Hypertension
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH
TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)
Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension
A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)
Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
A Pharmacokinetic Substudy of the TDE-PH-304 Protocol
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
Safety and Efficacy of Inhaled Treprostinil in Patients With PAH
Inhaled Treprostinil for PAH: Open-label Extension
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants
A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients
Imatinib (QTI571) in Pulmonary Arterial Hypertension
An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension
A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)
Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension
A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).
Apabetalone for Pulmonary Arterial Hypertension
A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)
A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Acute Haemodynamic Study of TPN171H in Patients with Pulmonary Arterial Hypertension
Safety and Efficacy of BIA 5-1058 in PAH
Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat)
Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension
Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients
Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH
Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension
Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT